or Try an Advanced Search...

    Technical Analysis for VSTM - Verastem, Inc.

    Grade Last Price % Change Price Change
    C 13.12 -0.30% -0.04
    VSTM closed down 0.3 percent on Wednesday, May 15, 2024, on 1.19 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical VSTM trend table...
    Date Alert Name Type % Chg
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    New Uptrend Bullish -0.30%
    Expansion Breakout Bullish Swing Setup -0.30%
    Pocket Pivot Bullish Swing Setup -0.30%
    Wide Bands Range Expansion -0.30%
    Above Upper BB Strength -0.30%
    Older End-of-Day Signals for VSTM ...

       Recent Intraday Alerts

    Alert Time
    Down 1% about 20 hours ago
    1.5x Volume Pace about 20 hours ago
    Up 2% about 20 hours ago
    Fell Below Upper Bollinger Band about 20 hours ago
    Rose Above Previous Day's High about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    VSTM Chart by TradingView
    Basic chart:

    Profile

    Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company's lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The company's product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Oncology Stem Cell Breast Cancer Ovarian Cancer Treatment Of Breast Cancer Signal Transduction mTOR Cancer Research Companion Diagnostic Metastasis Advanced Cancer Mesothelioma Advanced Cancers Cancer Stem Cell Cancer Stem Cells Mtor Inhibitors

    Is VSTM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 9 Verastem GAAP EPS of -$1.26
    May 9 Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
    May 7 Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
    Apr 18 Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
    Apr 4 Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Mar 18 Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
    Mar 14 Recap: Verastem Q4 Earnings
    Mar 14 Verastem GAAP EPS of -$1.02 misses by $0.21
    Mar 14 Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
    Mar 11 Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
    See more VSTM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.18
    52 Week Low 4.7412
    Average Volume 123,438
    200-Day Moving Average 9.72
    50-Day Moving Average 11.18
    20-Day Moving Average 10.75
    10-Day Moving Average 11.80
    Average True Range 0.66
    RSI (14) 70.67
    ADX 28.75
    +DI 38.21
    -DI 10.34
    Chandelier Exit (Long, 3 ATRs) 11.53
    Chandelier Exit (Short, 3 ATRs) 11.02
    Upper Bollinger Bands 13.20
    Lower Bollinger Band 8.30
    Percent B (%b) 0.98
    BandWidth 45.60
    MACD Line 0.45
    MACD Signal Line 0.10
    MACD Histogram 0.3505
    Fundamentals Value
    Market Cap 331.52 Million
    Num Shares 25.3 Million
    EPS -3.89
    Price-to-Earnings (P/E) Ratio -3.37
    Price-to-Sales 51.84
    Price-to-Book 4.01
    PEG Ratio -1.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 13.86
    Resistance 3 (R3) 13.91 13.72 13.74
    Resistance 2 (R2) 13.72 13.53 13.69 13.70
    Resistance 1 (R1) 13.42 13.41 13.32 13.37 13.66
    Pivot Point 13.22 13.22 13.17 13.20 13.22
    Support 1 (S1) 12.92 13.03 12.83 12.87 12.58
    Support 2 (S2) 12.73 12.92 12.70 12.54
    Support 3 (S3) 12.43 12.73 12.50
    Support 4 (S4) 12.38